LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

Healthcare Weekly News and Deals – November 14th, 2025

1. **Pfizer (NYSE: PFE) completes $7 Billion acquisition of Metsera (NASD: MTSR), adds MET-097i, MET-233i, and Expands Clinical Obesity Pipeline in Strategic Move for Cardiometabolic Therapeutics Leadership**

   Following the acquisition of Metsera, Pfizer broadens its internal medicine portfolio with a suite of innovative obesity and cardiometabolic drug candidates in advanced clinical and preclinical development, including weekly/monthly injections and oral therapies. Integrating Metsera's pipeline enables Pfizer to accelerate development in a rapidly growing therapeutic area, leveraging its global infrastructure and new scientific expertise. Financial terms include milestone-based payments through contingent value rights, with future strategic investment updates pending. The deal positions Pfizer for leadership in obesity and metabolic disease treatments, enhancing global access to quality care and cutting-edge therapies. (Link)

2. **Day One Biopharmaceuticals (NASD: DAWN) to acquire Mersana Therapeutics (NASD: MRSN) in $285 Million Deal to Advance Novel ADC Emiltatug Ledadotin for Adenoid Cystic Carcinoma and expanded Oncology Portfolio**

   Emiltatug ledadotin (Emi-Le), added to Day One Biopharmaceuticals' portfolio through the acquisition, has demonstrated early promise in Phase 1 trials for adenoid cystic carcinoma by targeting the B7-H4 protein, which is expressed in diverse cancers. The investigational therapy shows monotherapy anti-tumour activity in a highly underserved patient group and could progress rapidly toward approval. The transaction structure includes multiple clinical, regulatory, and financial milestones, with milestone payments tied to approvals and sales achievements. Day One aims to advance Emi-Le through clinical development and potential commercialization without needing further funding, subject to regulatory review and closing conditions. (Link)

3. **Galecto (NASD: GLTO) acquires Damora Therapeutics, With $285M Investment Led by Fairmount, Viking Global, Venrock, Wellington, RA Capital, Andreessen Horowitz, and Others to Advance Anti-mutCALR Therapies for Blood Cancers**

   The merger strengthens development for myeloproliferative neoplasm treatments, combining deep expertise and complementary assets. The pipeline includes DMR-001, an advanced monoclonal antibody with improved potency for Type 1 and Type 2 mutCALR-driven disease, and engineered for infrequent, low-volume dosing. Additional investigational therapies such as GB3226 expand the reach toward acute myeloid leukaemia. New capital ensures advancement through critical Phase 1 milestones, including innovative clinical trial designs and improved access for patients with rare blood cancers. Board restructuring and strategic guidance create a foundation for accelerated research, regulatory interactions, and delivery of transformative therapies across multiple hematologic indications. (Link)

4. Fabric acquires UCM Digital Health, adding 400 Payer and Employer Clients, to expand AI-Powered Virtual Care Nationwide

   Fabric’s acquisition brings over one million new covered lives and strengthens its presence among payers and employers, further cementing its status as a leader in AI-enabled virtual care. This deal marks Fabric’s fifth acquisition in under three years, expanding its customer base to 75 health systems, 30,000 employers, and more than 100 million patients. Fabric enhances its clinical network, efficiency, and ability to offer rapid, seamless care experiences and improved outcomes, while saving costs and closing care gaps for patients, providers, and payers across the U.S. (Link)

5. Luma Health acquires Tonic Health from R1, Expanding Patient Intake and Follow-Up Solutions for Over 1,000 Health Systems and 100 Million Patients, for EHR-Integrated Care Innovation

   By acquiring Tonic Health, Luma Health is enhancing its platform with new technologies for patient data collection, e-consent, and seamless care coordination. The integration offers advanced automation for intake and follow-up tasks, reducing manual workload and improving scheduling, readiness, and communication. With expanded capabilities, healthcare organizations benefit from reduced staff friction, streamlined integration with electronic health records, and a strengthened ability to support patients throughout their medical journeys. Luma’s innovations support more effective, scalable operations for health systems in the U.S. and internationally, ultimately improving access to care and patient satisfaction for millions. (Link)

6. Emergence, backed by The Pritzker Organization, acquires MedEvolve, to Transform AI-Driven Revenue Cycle Management for Healthcare Providers

   Under new ownership, MedEvolve is set to expand its investments in data science, automation, and AI analytics, building on its legacy of workflow optimization for healthcare revenue cycles. Its proprietary platform tracks millions of actions to provide benchmarking and performance oversight, enabling organizations to rapidly identify inefficiencies and reclaim lost margin. As financial pressures and payer claim denials rise, MedEvolve’s solutions empower providers with actionable data to streamline processes, maximize collections, and ensure operational transparency. The partnership aims to accelerate next-generation product development and deliver scalable, sustainable improvements in efficiency for healthcare orgs nationwide. (Link)

7. Get Well and RhythmX AI Combine Under SymphonyAI Group, to Form GW RhythmX and Advance Precision Care AI for 150 Health Systems and 85 million Patients

   GW RhythmX merges Get Well's patient engagement expertise with RhythmX AI's precision care platform, creating an integrated solution for health system clients across the U.S. and beyond. The new company leverages advanced, responsibly validated AI to deliver clinical insights, personalized recommendations, and optimize outcomes for patients, clinicians, and nurses. GW RhythmX unifies payer, clinical, and social health data for enterprise-scale care delivery, with a track record of reducing hospital readmissions and raising patient satisfaction. Now led by Deepthi Bathina, the combined entity accelerates digital transformation in healthcare, serving over 150 systems and impacting more than 85 million lives. (Link)

8. Diversis Capital Unites Genesis Automation Healthcare, Kermit, and Meperia to Launch First End-to-End Clinical Supply Chain Platform and Highlight $1B in Global Annual Savings for 100+ Hospitals and Health Networks

   The newly unified Genesis platform offers hospitals and ambulatory surgery centers a fully integrated solution for managing every aspect of their supply chain, from tracking consumables and high-value implants to optimizing charge capture and contract pricing. With cloud-based analytics, automated workflows, and bi-directional EHR/ERP integration, the system addresses waste, compliance gaps, and data quality issues that hinder operational efficiency. Hospitals using the platform report reduced costs, stronger purchasing controls, and easier, accurate product traceability—empowering clinicians to spend less time on inventory and more time focused on patient care, while finance teams benefit from real-time spend visibility and clean data. (Link)

9. Vituity Integrates Focus Medical Imaging, Expands Physician-Led Model Into Diagnostic and Interventional Radiology for Hospitals and Health Systems Nationwide

   By joining together, Vituity and Focus Medical Imaging enhance their clinical offerings, providing both diagnostic and interventional services that address pressing challenges like radiologist shortages and slow turnaround times. The partnership employs a physician-driven approach, supporting democratic clinical governance and empowering medical professionals with a strong voice in organizational decisions. Subspecialty depth and innovative teleradiology infrastructure further boost operational excellence. These combined resources and solutions allow hospitals, health systems, and imaging centers across the nation to optimize care delivery, improve efficiency, and ensure sustainable growth through active physician leadership and clinical coordination. (Link)

10. OneOncology and Cancer Specialists of North Florida (CSNF) Forge Partnership, via its financial sponsor TPG, to Elevate Community-Based Cancer Care and Expand Integrated Oncology Services Across North Florida

    The partnership empowers forty-two thousand patients at thirteen clinics in North Florida with expanded oncology offerings, seamless clinical research access, and advanced imaging innovations. CSNF's newly opened Jacksonville facility delivers comprehensive, low-cost care, reducing wait times and enabling real-time treatment decisions. Through collaboration, CSNF retains independence while gaining technological, operational, and precision medicine resources, supporting growth and high-quality cancer care delivery. The alliance strengthens community access to immunotherapies, radiation oncology, pharmacy, and labs, backed by research, provider ownership, and shared clinical expertise, fostering integrated cancer care across the region. (Link)

11. Hyve acquires Health Grown Advisory Network (HGAN), Strengthening Healthcare Innovation Partnerships and Behavioural Health Tech Integration

    Hyve's acquisition establishes continuous engagement channels between digital health industry leaders and partners, including Spring Health, Virta, Rightway, and Maven. HGAN brings advisory insight on marketing and system navigation, deepening Hyve's healthcare division beyond annual event cycles. This integration enables curated, year-round connections and strategic support for healthcare innovators and organizations. CEO Mark Shashoua and HGAN founder Josh Riff will drive further expansion, leveraging HLTH and Behavioural Health Tech assets. Hyve's investment supports enhanced collaboration, real-world partnerships, and scalable platform growth—extending value to health consumers and broadening potential rollout across its portfolio. (Link)

12. The Lockwood Group acquires Research To Practice (RTP), via its financial sponsor Ares Management, expanding Global Oncology Education

    The Lockwood Group's acquisition strengthens its medical education and communications offerings, especially for oncology professionals worldwide. RTP brings decades of expertise in accredited, evidence-based continuing education, producing live events, multimedia, and podcasts anchored in real-world cancer treatment advances. The partnership pairs Lockwood's regulatory consulting and visualization strengths with RTP's respected educational formats and connections to clinical thought leaders. Together, the organizations aim to empower clinicians through innovative, accessible content and to raise standards for patient care by providing actionable, evidence-based information and expanding their global educational impact across the rapidly evolving oncology landscape. (Link)

Venture and Other News

1. House Rx raises $55 Million Series B Led by New Enterprise Associates, Town Hall Ventures, LRVHealth, First Round Capital and Bessemer Venture Partners to Expand AI-Enabled In-Clinic Specialty Pharmacy Model

   House Rx operates a nationwide network of locally owned specialty dispensaries embedded in specialty clinics, aiming to improve patient access and affordability for complex medication needs. Its platform integrates clinical care and pharmacy services for seamless processes, faster treatment initiation, and reduced administrative burdens. With more than 1,000 partnered providers and $1.5 billion in annual specialty prescriptions, House Rx uses proprietary AI workflows to automate critical pharmacy functions and boosts efficiencies. The company is scaling operations to meet growing demand while investing in further AI-driven features to redefine specialty pharmacy care. (Link)

2. TandemAI raises $22M Series A Extension With V-Capital, KHK Fund, OrbiMed, Chengwei Capital and Sequoia Capital and Perpetual Medicines to Advance AI Drug Discovery Partnerships

   TandemAI has expanded its funding to grow its AI-driven drug discovery platform, integrating computational physics, advanced modelling, and wet lab capabilities. Supported by a team of over 300 and a strategic merger with Perpetual Medicines, the company enhances small molecule and peptide drug programs. Already collaborating with top pharmaceutical partners, TandemAI's platform delivers pipeline candidates into clinical development and accelerates global innovation through industry partnerships. The investment supports model development across modalities, wet lab expansion, and deeper expertise, marking significant progress in end-to-end drug design efficiency and clinical translation. (Link)

3. Joy raises $14 Million Series A from Forerunner, Raga Partners, Magnify Ventures, Ingeborg Investments and Next Legacy Partners to Launch AI Parenting Platform

   Joy's new app aims to address some of parenting's core challenges by uniting AI-trained expertise with round-the-clock access to certified human coaches for real-time guidance. Parents receive evidence-based advice, milestone tracking, and tailored product recommendations, reducing decision fatigue and feelings of isolation. The unified platform fosters community support, meaningful connections, and practical resources for every stage of child development. With its broadening network and improved AI, Joy is positioned to empower families worldwide, guiding parents with trustworthy information while streamlining their experience into one accessible, comprehensive support system that encourages confidence and connection throughout the parenting journey. (Link)

4. Modulight Biotherapeutics secures $12.2 Million Seed Round Led by Jibe Ventures, Nexus Neurotech, RedSeed VC, Fresh Fund, Saras Capital and SilverArc Capital Management to Advance Optogenetic Therapies

   Modulight Biotherapeutics is advancing a new era in neuromodulation, using optogenetics to enable precision control of neural circuits with light, avoiding damage and systemic side effects common in traditional treatments. Its proprietary opsin technology, eOPN3, is designed for outpatient use and pathway-specific inhibition, initially targeting trigeminal pain but showing efficacy in models of epilepsy and Parkinson's as well. Funds will accelerate preclinical milestones, manufacturing preparations, and regulatory engagement, leveraging licensed technology to pioneer safe, effective interventions for challenging brain disorders. The approach holds promise for more personalized, rapid relief, transforming neurological care. (Link)